Search trials – HealthDB

Активни:

Намерени 4,781 изпитвания Стр. 168 от 240

Not yet recruiting

The Effect of Apple Cider Vinegar Supplementation on 24-hour Urine Chemistry in Adults

Kidney Stones Urine Specimen Collection

This is a single-center prospective cohort study to evaluate the effect of short-term daily apple cider vinegar (ACV) supplementation on urine chemistry.

Начало: 01.05.2026 Край: 01.02.2028 Възраст: от 18 г.

United States University of Chicago NCT07389226

Not yet recruiting

Adapting a Brief Suicide Intervention for Pediatric Primary Care: Enhancing Uptake and Impact

Suicide Prevention

Suicide is a leading cause of death among adolescents in the United States and improving access to high quality just-in-time suicide interventions to reduce risk has important public health implications. Integrating such interventions into routinely accessed settings, such as pediatric primary care, holds promise; however, many clinicians in these settings fail to adequately screen or intervene in youth suicidal thoughts and behaviors, representing a key barrier to reducing suicide. The proposed study is a pre-post quasi-experimental pilot feasibility and preliminary efficacy trial of a suicide prevention intervention informed by evidence based interventions including the SAFETY-Acute suicide prevention intervention implemented in 3 pediatric primary care clinics.

Начало: 01.05.2026 Край: 01.03.2028 Възраст: от 10 г.

University of Washington NCT06499740

Not yet recruiting

Study of a Smart Sharps Disposal Device in Patients With Hemophilia

Hemophilia A and B

This pilot study will have patients use a smart sharps disposal container at home for disposal of needles used to administer their hemophilia drugs. The study aims to find out if the smart sharps container proved acceptable to use by patients and medical providers and can be adhered to.

Начало: 01.05.2026 Край: 30.01.2027 Възраст: от 18 г.

United States University of Pennsylvania NCT07421154

Not yet recruiting Phase 2

Lipid Infusions to Optimize Nutrition Trial

Bronchopulmonary Dysplasia Neurodevelopmental Impairment

The purpose of this study is to identify survival free of bronchopulmonary dysplasia (BPD), fatty acid profiles, and early biochemical measures for oxidative stress comparing mixed oil lipid emulsion (MOLE) vs soybean oil-based lipid emulsion (SOLE) and to establish whether MOLE or SOLE is more effective in minimizing pulmonary outcomes, neonatal morbidities, long-term morbidity and mortality, and improving discharge growth and Bayley Scales of Infant Development Fourth Edition (BSID-IV) neurodevelopmental assessment at two years

Начало: 01.05.2026 Край: 31.12.2030 Възраст: 12–28 г.

United States The University of Texas Health Science Center, Houston NCT06915441

Not yet recruiting

Safety Evaluation of Bioactive Glass Based Bone Cement Combined With Ultrasound in Implantation for Metastatic Bone Tumors

Advanced Cancer Pain

This study is evaluating the safety of using bioactive glass-containing bone cement combined with ultrasound during surgery for patients with metastatic bone tumors. We aim to see if this treatment can be safely applied to stabilize the bone and reduce pain, without causing unexpected side effects. All participants will receive standard care plus the study treatment, and we will closely monitor them during and after the procedure to check for any safety concerns.

Начало: 01.05.2026 Край: 30.04.2028 Възраст: 18–80 г.

Liao Yun NCT07540468

Not yet recruiting

Clinical Study to Confirm the Safety and Performance of the Virtuoso Phaco-vitrectomy Device

Cataract Vitrectomy Vitrectomy Operation Under General Anesthesia

This is a pre-market clinical investigation with a device that does not bear the CE-marking. Aim of the study is to confirm the safety and performance of the device and collect user feedback.

Начало: 01.05.2026 Край: 01.11.2026 Възраст: от 18 г.

Beaver-Visitec International, Inc. NCT06799156

Not yet recruiting

Effect of Descemet Membrane Polishing in Fuchs Endothelial Corneal Dystrophy

Fuchs Endothelial Corneal Dystrophy

Fuchs endothelial corneal dystrophy (FECD) is the leading indication for corneal transplantation worldwide. It is characterized by the accumulation of guttae and progressive loss of corneal endothelial cells, leading to corneal edema and visual impairment. Endothelial keratoplasty remains the standard treatment; however, graft shortages have driven the development of cell-based therapies involving the injection of cultured endothelial cells. A key unresolved issue is whether removal of the pathological endothelium prior to injection improves cell adhesion. Clinical data are limited and sometimes contradictory, particularly regarding endothelial polishing. The actual effectiveness of this procedure in removing guttae and enhancing the survival of injected cells remains uncertain. Therefore, an in vivo clinical evaluation is required to assess its impact on guttae removal.

Начало: 01.05.2026 Край: 01.03.2027 Възраст: от 18 г.

France Centre Hospitalier Universitaire de Saint Etienne NCT07539012

Not yet recruiting

Understanding the Relationship of Body Composition and Metabolism in Adult and Older Filipino Endurance and Strength Athletes in the Philippines

Nutrition Physiology Athletes The Focus of This Study is to Describe the Body Composition and Metabolism of Athletes and Non-athletes

This study aims to address the gap by investigating the correlation between body composition and metabolism in adult and older Filipino endurance and strength athletes. It seeks to offer significant insights that can guide age- and sport-specific training programs, nutritional strategies, and health interventions adapted to the requirements of Filipino athletes. The results may help enhance the wider discussion on fostering healthy aging and athletic longevity in the Philippines.

Начало: 01.05.2026 Край: 31.01.2027 Възраст: 20–69 г.

Food and Nutrition Research Institute, Philippines NCT07548515

Not yet recruiting

Video Versus Direct Laryngoscopy for Tracheal Intubation in Pediatric Surgery

Tracheal Intubation Videolaryngoscopy General Anesthesia Difficult Airway Intubation

Tracheal intubation in paediatric patients is a high-risk procedure in which failure to achieve successful intubation on the first attempt is associated with an increased risk of complications, including hypoxaemia and airway trauma. Videolaryngoscopes have been increasingly adopted in clinical practice because they improve glottic visualisation; however, evidence of their benefit in paediatric patients remains inconsistent. The VIDEOKIDS trial is a large, pragmatic, international, multicentre, randomised controlled trial designed to compare videolaryngoscopy with direct laryngoscopy as the initial technique for tracheal intubation in paediatric patients undergoing surgery under general anaesthesia. The primary objective is to determine whether videolaryngoscopy increases the rate of successful intubation on the first attempt compared with direct laryngoscopy.

Начало: 01.05.2026 Край: 30.12.2027 Възраст: до 16 г.

Spain Hospital Clinico Universitario de Santiago NCT07495436

Not yet recruiting

Outcome of Hyaluronic Acid Gel Versus Petroleum Jelly in Treatment of Epistaxis

Epistaxis

The aim of this study is to compare the efficacy of Hyaluronic Acid Gel with Petroleum Jelly in treatment of epistaxis.

Начало: 01.05.2026 Край: 01.06.2028

Assiut University NCT07531472

Not yet recruiting Phase 1

MDMA Assisted Therapy for BN

Bulimia Nervosa

This project will evaluate MDMA Assisted Therapy (MDMA-AT) assisted psychotherapy for the treatment of Bulimia Nervosa (BN) over a 10-week period. Preliminary data suggests that MDMA can facilitate heightened openness and reduce anxiety. This study will determine whether MDMA-assisted therapy can serve as a new treatment for BN. Participants are assigned to one of three groups: MDMA-AT, MDMA-AT-BN, and Standard Treatment (ST). MDMA groups include three experimental session that include dosing, which are each followed by three integrative sessions and also include 12 psychotherapy sessions. A follow-up will take place at 6-months post baseline.

Начало: 01.05.2026 Край: 30.04.2028 Възраст: от 18 г.

United States Icahn School of Medicine at Mount Sinai NCT07542145

Not yet recruiting Early Phase 1

Effects of Peripheral Repetitive Peripheral Magnetic Stimulation on Individuals With Elbow or Wrist Chronic Pain

Tennis Elbow Syndrome Golfer's Elbow Carpal Tunnel Syndrome (CTS)

This pilot, randomized, sham-controlled, single-blind study will evaluate the effectiveness of repetitive peripheral magnetic stimulation (rPMS) in reducing pain in adults with tennis/golfer's elbow or carpal tunnel syndrome. Approximately 40 participants will be randomly assigned to active or sham stimulation delivered over two consecutive days. Outcomes, including pressure pain threshold, subjective pain ratings, and local tissue oxygenation (fNIRS), will be assessed at baseline, immediately post-intervention, and during follow-up up to 6 months to evaluate both clinical effects and underlying physiological mechanisms.

Начало: 01.05.2026 Край: 30.12.2027 Възраст: от 18 г.

University of Manitoba NCT07544914

Not yet recruiting

Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer

Carcinoma, Non-Small-Cell Lung (NSCLC) Neoplasm Staging Lymphatic Metastasis

Background: For patients with resectable stage III-N2b non-small cell lung cancer (NSCLC), optimal perioperative treatment strategies remain an area of active investigation. Iparomlimab and tuvonralimab (QL1706) is a novel bifunctional antibody combination targeting PD-1 and CTLA-4, designed to enhance anti-tumor immunity. Objective: This phase II, single-arm, multicenter study aims to evaluate the efficacy and safety of neoadjuvant iparomlimab and tuvonralimab (QL1706) in combination with platinum-based chemotherapy in patients with resectable stage III-N2b NSCLC. Study Design and Methods: A total of 28 patients will be enrolled across approximately 4 centers in China. Eligible patients (aged ≥18 years, ECOG PS 0-1) with histologically or cytologically confirmed, resectable stage III-N2b NSCLC (AJCC 9th edition) will receive three cycles of neoadjuvant therapy every three weeks. Patients with non-squamous carcinoma will receive iparomlimab and tuvonralimab (5 mg/kg) plus pemetrexed (500 mg/m²) and carboplatin (AUC 5). Patients with squamous carcinoma will receive iparomlimab and tuvonralimab (5 mg/kg) plus nab-paclitaxel (260 mg/m²) and carboplatin (AUC 5). Surgical resection will be performed within 6 weeks following completion of neoadjuvant therapy. Subsequent adjuvant treatment is at the discretion of the investigator. Key Eligibility Criteria: Key inclusion criteria include pathologically confirmed T\any\N2b disease with mediastinal nodal status confirmed by EBUS/EUS or mediastinoscopy, and the determination by multidisciplinary team (MDT) assessment that the tumor is completely resectable (R0). Key exclusion criteria include known EGFR or ALK positive mutations, prior anti-cancer therapy for current lung cancer, active autoimmune disease, or uncontrolled hepatitis B or C. Study Endpoints: The primary endpoint is the pathological complete response (pCR) rate. Secondary endpoints include major pathological response (MPR) rate, objective response rate (ORR), R0 resection rate, event-free survival (EFS), overall survival (OS), impact on surgical outcomes, and safety. Exploratory endpoints involve biomarker analysis including ctDNA. Sample Size Rationale: Assuming a null hypothesis pCR rate (P0) of 8.8% (based on historical data) and an expected pCR rate (P1) of 28%, with a two-sided α of 5% and 80% power, 24 patients are required. Factoring in a 15% inoperable rate, the total sample size is 28 patients. Statistical Analysis: The primary endpoint, pCR rate, and other binary endpoints will be summarized with frequencies, percentages, and their 95% confidence intervals calculated using the Clopper-Pearson method. Time-to-event endpoints (EFS, OS) will be analyzed using the Kaplan-Meier method. Safety data will be summarized descriptively. Clinical Trial Information: This study is sponsored by The Second Affiliated Hospital of Air Force Medical University, PLA. The Principal Investigator is Dr. Yan Xiaolong.

Начало: 01.05.2026 Край: 01.12.2029 Възраст: от 18 г.

China Tang-Du Hospital NCT07538193

Not yet recruiting Phase 2/3

MInimizing Delirium With Nasal Dexmedetomidine-InducEd Sleep (MIDDIES)

Major Abdominal Surgery Postoperative Delirium (POD) Sleep Disturbances Intranasal Dexmedetomidine

This study aims to determine whether, compared with placebo, the nighttime self-administration of a nasal dexmedetomidine is effective at inducing sleep and preventing postoperative delirium in high-risk patients.

Начало: 01.05.2026 Край: 30.06.2027 Възраст: 65–90 г.

Sixth Affiliated Hospital, Sun Yat-sen University NCT07538284

Not yet recruiting

Efficacy and Safety of CDED With Anti-TNF-α Biologics in Crohn's Disease

Crohn Disease

Crohn's disease (CD) is a chronic inflammatory bowel disease with high recurrence and surgical rates. Mucosal healing is a key therapeutic goal, yet current anti-TNF-α biologics achieve only about 30% mucosal healing. Dietary intervention, particularly the Crohn's Disease Exclusion Diet (CDED), shows promise in CD management. Preliminary data suggest that combining CDED with anti-TNF-α biologics may significantly improve mucosal healing rates (42.9% vs 25%). This single-center, prospective, randomized, controlled trial will enroll 185 adult CD patients with active disease (SES-CD ≥3), randomly assigned 1:1 to receive either anti-TNF-α biologics plus CDED or anti-TNF-α biologics alone. The primary endpoint is mucosal healing rate at week 14 (SES-CD=0). Secondary endpoints include clinical remission, endoscopic response, transmural healing, and adverse events. This study aims to provide high-quality evidence for the efficacy and safety of this combined approach in Chinese CD patients.

Начало: 01.05.2026 Край: 01.05.2028 Възраст: от 18 г.

China Sixth Affiliated Hospital, Sun Yat-sen University NCT07344428

Not yet recruiting Phase 1

Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)

Myelofibrosis

The purpose of this clinical trial is to learn if the study drug ropeginterferon alfa- 2b added to, standard of care, ruxolitinib is safe and effective in treating patients with Myelofibrosis.

Начало: 01.05.2026 Край: 01.05.2030 Възраст: от 18 г.

United States University of Utah NCT07521046

Not yet recruiting

Evaluation of Accelerated Bachmann Bundle Area Pacing in Heart Failure With Reduced ejectIon Fraction Who Have electrocarDioGraphic Evidence of Interatrial Block and Indicated for Implantable Cardioverter Defibrillator

Heart Failure and Reduced Ejection Fraction

To evaluate the effect of accelerated atrial resynchronization achieved through Bachmann bundle pacing at the time of implantable cardioverter-defibrillator implantation in patients with heart failure with reduced ejection fraction and interatrial block

Начало: 01.05.2026 Край: 31.12.2030 Възраст: от 18 г.

Seoul National University Hospital NCT07547306

Not yet recruiting

Diagnostic Accuracy and Prognostic Value of 18F FDG PET-CT in the Follow up of Patients With Colorectal Carcinoma.

Rectal Cancer (Stage III)

The goal of this observational study is to learn about the diagnostic and prognostic value of 18f fdg pet ct in follow up of colorectal cancer patients The main question it aims to answer is: Does pet ct have a role in treatment decision in colorectal cancer patients? Participants already be undergoing for pet ct as part of their follow up routine and will be followed up for 5 years.

Начало: 01.05.2026 Край: 05.03.2031

Assiut University NCT07536321

Not yet recruiting

An International Federated Model for Wearable-derived Remote Longitudinal Motor Monitoring in Young Children With Spinal Muscular Atrophy Compared With Healthy Controls: Active-NBS Study (UK)

Spinal Muscular Atrophy (SMA)

Active-NBS is a study to evaluate the muscle development of patients with spinal muscular atrophy (SMA) who are diagnosed at birth. Medicines have become available in the last decade, and many patients are treated very early. Treatments are most effective if used before the patient develops symptoms. However, some patients may show symptoms by the time they receive treatment. This means that even with early diagnosis, they might still develop muscle weakness despite treatment. The investigators want to see when the movements of patients diagnosed at birth differ from normal development. This information will help identify the best time to give additional medicines currently being developed to support the muscle. The investigators will track the progress of up to 60 patients over a maximum of 30 months using wearable technologies which are worn at home. The investigators aim to validate their outcomes for use in this age group. The wearable devices are called Syde and Motor Assessment of an Infant in a Jumpsuit (MAIJU). They will be worn at regular intervals during the study and will not involve extra hospital visits for patients. The study will also recruit up to 30 healthy control participants and follow them for up to 30 months. This will help define normal development with use of the Syde device. Active-NBS will be conducted in the UK and internationally using a federated data model. Collaborative sites will collect harmonised data in accordance with the Active-NBS protocol, with data integration and oversight managed by the University of Oxford. International sites may contact the Oxford study team to establish collaboration.

Начало: 01.05.2026 Край: 01.07.2029 Възраст: до 4 г.

United Kingdom University of Oxford NCT07543003

Not yet recruiting Phase 1

A Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function

Diabetes Mellitus Weight Loss

This is a Phase I clinical study to compare the pharmacokinetics (PK) of HRS9531 Injection in participants with mild/moderate hepatic impairment and participants with normal hepatic function, and to evaluate the safety of HRS9531 Injection in these participants.

Начало: 01.05.2026 Край: 01.02.2027 Възраст: 18–65 г.

China Fujian Shengdi Pharmaceutical Co., Ltd. NCT07540754

1 … 166 167 168 169 170 … 240